Medtronic plc 's MDT brain therapy business gets a boost with the recent FDA approval for the company's latest Deep Brain Stimulation (DBS) Clinician.

Having to manually program settings can be a time-consuming process. Medtronic’s SureTune2 aims to alleviate some of the frustrations of this process. Using visualization of patient-specific ...

The SenSight directional DBS lead system works seamlessly with certain Medtronic neurostimulators, including the recently-approved Percept™ PC neurostimulator.

To help clinicians and patients better optimize the therapy, Medtronic sought user-friendly mobile devices to adjust the programming of DBS implants and to put more control into the patient’s hands.

The U.S. FDA approval also includes the Medtronic BrainSense™ Electrode Identifier (EI), which helps reduce patient time spent in clinic to program their DBS settings.

Medtronic Percept™ DBS therapy is the only sensing-enabled † DBS system available, allowing a physician to use data from a patient’s brain activity to personalize their treatment.

Medtronic was the first in the United States to offer full-body MR Conditional DBS systems for patients to have safe scans anywhere on the body under certain conditions.

Medtronic has recalled the auto-registration feature in the StealthStation deep brain stimulation (DBS) software because of inaccuracies during DBS procedures, according to a notice on the US Food ...

The FDA approved Medtronic's BrainSense Adaptive DBS and Electrode Identifier for Parkinson's, enhancing therapy personalization and clinic efficiency.

--Medtronic plc, the global leader in medical technology, today announced the CE Mark for the SenSight™ directional lead system for Deep Brain Stimulation therapy as treatment of symptoms ...